| Strategic International Session3（S）(JSGS・JSGE・JGES) |
| Fri. November 1st 14:00 - 17:00 Room 11: Portopia Hotel South Wing Topaz |
| Innovative Multidisciplinary Strategies for Treating Locally Advanced Esophagogastric Junction Adenocarcinoma | |||
| Izuma Nakayama | |||
| Department of Gastrointestinal Oncology, National Cancer Center Hospital East | |||
|
|||
|
|||
| Regarding pharmacological treatment, gastroesophageal junction cancer (GEJC) has been treated either as gastric cancer (GC) or, at times, as esophagus cancer, particularly in the West. Depending on the results of the upcoming MATTERHORN study, perioperative FLOT with durvalumab, an anti-PD-L1 therapy, will be established as the first global standard for locally advanced gastric cancer including GEJC. Chemoradiotherapy (CRT) has been an alternative standard approach for locally advanced upper gastrointestinal (GI) cancer. The ESOPEC trial might provide an answer to the debatable question of whether perioperative chemotherapy or CRT is the preferential approach. We are currently in the midst of a paradigm shift in the treatment of locally advanced upper GI cancers. I would like to highlight previous clinical trials with special focus on GEJ adenocarcinoma and suggest a next-generation multimodal approach to achieve further improvements. |
|||
|
Index Term 1: Total Neoadjuvant Therapy Index Term 2: Non-operative management |
|||
| Page Top | |||